Provides relative to peptides. (8/1/26)

Senate Bill 253 enacts a new statutory provision codified as R.S. 37:23.5 that restricts the regulatory authority of Louisiana's professional and occupational licensing boards over peptide prescribing. The legislation prohibits these licensing boards from preventing healthcare providers who possess prescriptive authority from dispensing peptides to patients when those peptides originate from either a FDA-registered 503B facility or a 503A compounding pharmacy that sources its active pharmaceutical ingredients from a FDA-registered manufacturer. The bill imposes a single requirement on prescribing providers: they must verify that any peptides they prescribe are not listed on the FDA's prohibited compounding list. The statute becomes effective August 1, 2026.

The practical effect of this legislation is to create a protected zone for peptide prescribing by licensed healthcare providers in Louisiana, removing the ability of state licensing boards such as those governing physicians, nurse practitioners, physician assistants, and other practitioners with prescriptive authority to establish rules or policies that would bar such prescribing. Healthcare providers with prescriptive authority may now offer peptides to their patients without fear of licensing board discipline, provided the source facility meets the specified FDA registration requirements. Conversely, licensing boards lose their traditional gatekeeping function over this specific category of compounded medications, which may affect their ability to ensure quality control, patient safety oversight, or professional practice standards in this area.

This legislation operates within the framework of Louisiana's professional licensing system established in Title 37 of the Revised Statutes, specifically targeting the regulatory relationship between the state's licensing boards and prescribing practitioners. The bill references FDA regulatory categories including 503B outsourcing facilities and 503A compounding pharmacies, which are pharmacy categories defined under federal law that govern the preparation and distribution of compounded medications. By invoking federal FDA registration requirements and the FDA's prohibited compounding list as the controlling standards, the legislation creates a dual regulatory scheme where federal approval and standards operate to preempt state licensing board authority within this narrow domain.